Person: DESTEK, SABAHATTİN
2 results
Search Results
Now showing 1 - 2 of 2
Publication Open Access Using pentraxin-3 for diagnosing acute appendicitis and predicting perforation: A prospective comparative methodological study.(2020-01-01T00:00:00Z) Gul, VO; Destek, SABAHATTİN; DESTEK, SABAHATTİNBACKGROUND: In this study, we aimed to investigate the diagnostic performance of pentraxin-3 for acute appendicitis, and the predictive performance for perforation in patients with acute appendicitis, compared with white blood cell count, high-sensitivity C-reactive protein and interleukin-6 (IL-6). METHODS: This study was a prospective methodological study, in which we studied the accuracies of the serum levels of pentraxin-3, white blood cell count, interleukin-6 and high-sensitivity C-reactive protein in estimating acute appendicitis, and in estimating perforation in patients with acute appendicitis. We designed the control group with the patients diagnosed inguinal hernia and admitted for elective surgery. Receiver operating characteristics analysis was used to compare the diagnostic accuracies and predictive performances. RESULTS: Receiver operating characteristics analysis revealed that the Pentraxin-3 level >3.67 ng/mL showed the sensitivity of 95.5% and specificity of 100.0% for diagnosing acute appendicitis, with an area under the curve of 0.993 (95% CI 0.967–1.000). Also, the Pentraxin-3 level >9.56 ng/mL showed the sensitivity of 92.9%, and the specificity of 87.1% for the prediction of the perforation, with an area under the curve of 0.820 (95% CI 0.736–0.886). CONCLUSION: The diagnostic performance of Pentraxin-3 for acute appendicitis and the predictive performance for perforation were higher than white blood cell count, high-sensitivity C-reactive protein and interleukin-6.Publication Metadata only Hereditary Thrombophilia Risk Factors In Patients With Venous Thromboembolism(2020-01-01T00:00:00Z) Destek, Sabahattin; Gül, Vahit Onur; DESTEK, SABAHATTİNVenous thromboembolic disease (VTD) is a serious cause of mortality and morbidity with an incidence of 0.1% per year. The etiology of VTD is multifactorial and associated with acquired and hereditary conditions. The aim of our study was to investigate the presence of rare genetic mutations in VTD patients and to evaluate their distribution according to thrombosis sites.The study group consisted of 107 patients who underwent genetic testing for thrombophilia due to VTD between 2015 and 2017. Patients with VTD who underwent thrombophilic genetic examination by polymerase chain reaction method were included in the study. Antithrombin III, protein C and protein S deficiency patients diagnosed with biochemical tests were excluded from the study. The demographic characteristics and clinical results of the patients were obtained from the hospital archive. The control group consisted of 112 healthy individuals randomly selected from the community. The patient group and the control group were compared.The mean age of the patients was 39.6 years. The female/male ratio was 1.7. Advanced age and female gender were statistically significantly more frequent in the patient group (In both, p=0.0001). Factor V G1691A and B-Fibrinogen-455 genetic defects were statistically significantly higher in the patient group (Respectively; p=0.008, p=0.049). The most frequent (54.2%) PAI-4G&5G heterozygous gene defect was found in the patients. Deep venous thrombosis was detected in 54.2%, intraabdominal VTD in 4.7%, pulmonary embolism in 27.1%, and cerebral venous thrombosis in 30.8% of the VTD patients.Thrombophilic genetic mutations are not uncommon in patients with VTD. Thrombophilic genetic mutations in VTD etiology and in selected patients should be investigated. In patients without known thrombophilia mutations, rare thrombophilic mutations should be examined.